Urogen Pharma Ltd Revenue Growth Rates (URGN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Urogen Pharma Ltd   (NASDAQ: URGN)
 

URGN's Revenue Growth by Quarter and Year

Urogen Pharma Ltd 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

URGN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 72.46
1st Quarter March 50.82
FY 123.28

URGNs Annual Revenue
Urogen Pharma Ltd 's Revenue in the fiscal year 2025 $ 109.34 millions
Urogen Pharma Ltd 's Revenue in the fiscal year 2024 $ 89.52 millions
Urogen Pharma Ltd 's Revenue in the fiscal year 2023 $ 82.35 millions
Urogen Pharma Ltd 's Revenue in the fiscal year 2022 $ 64.36 millions
Urogen Pharma Ltd 's Revenue in the fiscal year 2021 $ 48.04 millions




URGN Revenue second quarter 2026 Y/Y Growth Comment
Urogen Pharma Ltd reported Revenue surge of 206.11% year on year in the second quarter 2026, to $ 72.46 millions, this is lower than Urogen Pharma Ltd 's recent average Revenue surge of 299.71%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 25 other companies have achieved higher Revenue growth. While Urogen Pharma Ltd ' s Revenue doubling of 206.11% ranks overall at the positon no. 139 in the second quarter 2026.


URGN Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 54.01 % 4.42 % 30.07 %
3rd Quarter September - 9.9 % 20.79 % 27.27 %
2nd Quarter June 206.11 % 9.48 % 4.44 % 24.7 %
1st Quarter March 155.12 % 10.36 % 5 % 26.77 %
FY   - 22.07 % 8.64 % -

Financial Statements
Urogen Pharma Ltd 's second quarter 2026 Revenue $ 72.46 millions URGN's Income Statement
Urogen Pharma Ltd 's second quarter 2025 Revenue $ 23.67 millions Quarterly URGN's Income Statement


URGN Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 39.12 % -0.73 % 14.84 %
3rd Quarter September - 14.91 % 14.48 % -1.01 %
2nd Quarter June 42.57 % 18.83 % 19.78 % 20.42 %
1st Quarter March 34.3 % -18.93 % -23.29 % -4.98 %
FY (Year on Year)   - 22.07 % 8.64 % -


Back to URGN Growth rate Comparisons >> Back to URGN Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #43
Overall #139

Revenue Y/Y Growth Statistics
High Average Low
3403.23 % 299.71 % -100 %
(Mar 31 2022)   (Sep 30 2025)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #43
Overall #139
Revenue Y/Y Growth Statistics
High Average Low
3403.23 % 299.71 % -100 %
(Mar 31 2022)   (Sep 30 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Urogen Pharma Ltd 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
830.38 % 27.38 % -100 %
(Sep 30 2020)  


URGN's II. Quarter Q/Q Revenue Comment
Urogen Pharma Ltd achieved in the II. Quarter 2026 above company average sequential Revenue jump of 42.57%, to $ 72.46 millions, from $50.82 millions in the first quarter.
URGN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Urogen Pharma Ltd 's Revenue growth quarter on quarter, overall rank is 278.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #73
Overall #278
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #73
Overall #278
Revenue Q/Q Growth Statistics
High Average Low
830.38 % 27.38 % -100 %
(Sep 30 2020)  


URGN's II. Quarter Q/Q Revenue Comment
Urogen Pharma Ltd achieved in the II. Quarter 2026 above company average sequential Revenue jump of 42.57%, to $ 72.46 millions, from $50.82 millions in the first quarter.
URGN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Urogen Pharma Ltd 's Revenue growth quarter on quarter, overall rank is 278.


Urogen Pharma Ltd 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 188.32 $ 139.53 $ 108.63 $ 95.36 $ 92.91
Y / Y Revenue Growth (TTM) 102.7 % 53.56 % 22.07 % 8.42 % 11.01 %
Year on Year Revenue Growth Overall Ranking # 1404 # 1322 # 974 # 318 # 633
Seqeuential Revenue Change (TTM) 34.97 % 28.44 % 13.92 % 2.64 % 2.25 %
Seq. Revenue Growth (TTM) Overall Ranking # 2400 # 2138 # 1621 # 774 # 1794


Cumulative Revenue growth Comment
Urogen Pharma Ltd saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 102.7% year on year, to $ 188 millions if the fiscal year would have ended in Jun 30 2026.
Urogen Pharma Ltd 's trailing twelve months Revenue growth was higher than company's average 40.07% and higher than 53.56% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 34.97 % from $139.53 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at40.07%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 34.97 % increase from $139.53 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 240 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1322 to 1404.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 111
Healthcare Sector # 241
Overall # 1404

Revenue TTM Y/Y Growth Statistics
High Average Low
180.65 %
 40.07 %
8.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 111
Sector # 344
S&P 500 # 2400
Cumulative Revenue growth Comment
Urogen Pharma Ltd saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 102.7% year on year, to $ 188 millions if the fiscal year would have ended in Jun 30 2026.
Urogen Pharma Ltd 's trailing twelve months Revenue growth was higher than company's average 40.07% and higher than 53.56% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 34.97 % from $139.53 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at40.07%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 34.97 % increase from $139.53 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 240 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1322 to 1404.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 111
Healthcare Sector # 241
Overall # 1404

Revenue TTM Y/Y Growth Statistics
High Average Low
180.65 %
40.07 %
8.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 111
Sector # 344
S&P 500 # 2400




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
URGN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Vireo Growth Inc.335.47%$ 335.470 millions
Dianthus Therapeutics Inc 294.30%$ 294.301 millions
Miragen Therapeutics Inc 278.67%$ 278.667 millions
Alpha Cognition Inc.267.56%$ 267.556 millions
Agios Pharmaceuticals Inc 259.25%$ 259.253 millions
Omniab Inc 244.24%$ 244.239 millions
Medicinova Inc 240.60%$ 240.596 millions
Clene Inc 233.33%$ 233.333 millions
Editas Medicine Inc 232.31%$ 232.309 millions
Urogen Pharma Ltd 206.17%$ 206.174 millions
Sintx Technologies Inc 199.34%$ 199.338 millions
Arrowhead Pharmaceuticals Inc 171.02%$ 171.016 millions
Cue Biopharma Inc 166.66%$ 166.655 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________162.99%$ 162.992 millions
Cormedix Inc 156.52%$ 156.515 millions
Ataibeckley Inc 137.00%$ 136.996 millions
Pavmed Inc 135.71%$ 135.714 millions
Xilio Therapeutics Inc 131.22%$ 131.222 millions
Tenon Medical Inc 126.77%$ 126.773 millions
Sonida Senior Living Inc 122.02%$ 122.024 millions
Bridgebio Pharma Inc 120.39%$ 120.392 millions
Autolus Therapeutics Plc118.37%$ 118.367 millions
Neuraxis Inc 115.72%$ 115.717 millions
Renovorx Inc 115.40%$ 115.403 millions
Ars Pharmaceuticals Inc 114.15%$ 114.150 millions
Foghorn Therapeutics Inc 112.68%$ 112.677 millions
60 Degrees Pharmaceuticals Inc 106.04%$ 106.044 millions


About Urogen Pharma Ltd Revenue Growth Rates (URGN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Urogen Pharma Ltd (CIK 1668243).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-26-025794
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Urogen Pharma Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.